Immunic board adds CEO Erik Lundgren as director after Tamar Howson's retirement
The move follows Howson's June 29 departure from the board and its compensation committee, which Immunic says was unrelated to any dispute.
Immunic, Inc. disclosed in a Form 8-K dated July 6, 2026 that Tamar Howson stepped down from the company's board and its Compensation Committee on June 29, 2026. According to the filing, Howson's resignation came as she moved into retirement.1 The company stated that her departure did not stem from any disagreement with Immunic over its operations, policies, or practices.1
On July 5, 2026, the board named Erik Lundgren, who serves as the company's chief executive officer, to fill a Class II director seat. Per the filing, his appointment followed a recommendation from the Nominating and Corporate Governance Committee, and his term runs through the 2028 annual stockholder meeting, subject to standard provisions for succession, resignation, or removal.1
The filing specifies that no arrangements exist between Lundgren and any other party tied to his appointment, he has not been placed on any board committee, and he will not receive extra compensation for the director role.1 Separately, Lundgren's employment agreement with the company was disclosed previously in a Form 8-K filed May 27, 2026.1 The company added that apart from that employment agreement and his compensation as CEO, no transactions involving Lundgren require disclosure under Item 404(a) of Regulation S-K.1
The 8-K was signed by Lundgren in his capacity as chief executive officer.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.